STRYKER CORPORATION
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1946-01-01
- Employees
- 22K
- Market Cap
- -
- Website
- www.stryker.com
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Stryker Biotech
- Target Recruit Count
- 51
- Registration Number
- NCT01133613
- Locations
- 🇺🇸
Florida Medical Research Institute, Gainesville, Florida, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Stryker Biotech
- Target Recruit Count
- 355
- Registration Number
- NCT01111045
- Locations
- 🇺🇸
Arizona Arthritis and Rheumatology Research, Glendale, Arizona, United States
🇺🇸University of Arizona Arthritis Center, Tucson, Arizona, United States
🇺🇸Stanford University School of Medicine, Palo Alto, California, United States
A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee
- Conditions
- Osteoarthritis of the Knee
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- Stryker Biotech
- Target Recruit Count
- 33
- Registration Number
- NCT00456157
- Locations
- 🇺🇸
Tufts-New England Medical Center, Boston, Massachusetts, United States
🇺🇸Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸University of orth Carolina School of Medicine, Chapel Hill, North Carolina, United States
News
Stryker Receives FDA Clearance for OptaBlate BVN System to Treat Chronic Lower Back Pain
Stryker received FDA clearance for its OptaBlate BVN Basivertebral Nerve Ablation System, a minimally invasive treatment for chronic vertebrogenic lower back pain.
GLP-1 Agonists Expedite Preoperative Weight Loss in Obese Hernia Patients
• A retrospective study reveals that GLP-1 agonists accelerate preoperative weight loss in obese patients undergoing elective hernia repair. • The study showed GLP-1 agonists significantly reduce the time to surgery compared to lifestyle modifications alone, without increasing postoperative complications. • Findings suggest GLP-1 agonists could enhance patient retention in hernia programs, potentially increasing access to safe and durable hernia surgery. • The research highlights the need for further studies to evaluate the cost-effectiveness and long-term impact of GLP-1 agonists in surgical prehabilitation.